Dyadic International secured the full $3.1 million Gates Foundation grant for its monoclonal antibody programme while advancing Bundibugyo Ebola antigen delivery to Scripps Research Institute by end of July 2026 — a convergence of institutional validation and infectious disease partnership that strengthens the C1 platform's global health credentials.
Key Highlights
- Full Gates Foundation Grant Secured: Dyadic received the complete $3.1 million Gates Foundation grant for its monoclonal antibody programme — a symbolically powerful institutional endorsement from one of the world's most rigorous evaluators of global health technology.
- Bundibugyo Ebola Antigen Delivery: Initial purified Bundibugyo Ebola antigen samples are expected to be delivered to the Scripps Research Institute by end of July 2026 — demonstrating the C1 platform's versatility across different classes of challenging biological products.
- Cost Efficiency for Low-Income Markets: The C1 protein production platform's manufacturing cost structure is compatible with the extreme price sensitivity of low- and middle-income country healthcare markets, where conventional CHO cell-based manufacturing produces biologics at prohibitively expensive costs.
Why the Gates Foundation Endorsement Matters
The Gates Foundation's $3.1 million grant to Dyadic International for its monoclonal antibody programme carries significance that substantially exceeds the dollar value of the award. The Bill & Melinda Gates Foundation is one of the most rigorous and selective funders in global health research, applying scientific and commercial due diligence standards that are equivalent to — and in some respects more demanding than — those of major pharmaceutical companies evaluating potential licensing partners. A Gates Foundation grant is an endorsement of both the scientific quality and the commercial viability of a technology for deployment in the specific context of low- and middle-income country healthcare markets.
For Dyadic, the Gates Foundation endorsement validates the C1 protein production platform's primary competitive claim: the ability to manufacture biological therapeutics — including monoclonal antibodies — at a cost structure that is compatible with the price sensitivity of global health markets. Conventional Chinese hamster ovary (CHO) cell-based biological manufacturing — the industry standard for commercial biologics production — produces proteins at costs that are generally prohibitive for widespread deployment in sub-Saharan Africa, South Asia, and other regions where the disease burden is highest and the ability to pay for expensive biologics is most limited.
The C1 platform uses a different host organism — the filamentous fungus Myceliophthora thermophila, engineered for high-yield protein production — that Dyadic claims can produce biologics at substantially lower cost per gram than CHO-based manufacturing. The Gates Foundation's decision to fund the monoclonal antibody programme implies that the Foundation's technical team has evaluated this cost advantage claim and assessed it as credible and sufficient to justify investment in the Dyadic approach for global health applications.
The Bundibugyo Ebola Antigen Programme and Scripps Collaboration
The expected delivery of initial purified Bundibugyo Ebola antigen samples to the Scripps Research Institute by end of July 2026 represents a concurrent milestone that demonstrates the C1 platform's versatility across different categories of challenging biological products. Bundibugyo Ebola virus is one of five known Ebola species, having caused lethal outbreaks in Uganda (2007) and the DRC, with case fatality rates that make any vaccine or therapeutic antigen development a genuine global health priority.
Producing Ebola virus antigens outside of biosafety level 4 (BSL-4) containment — the highest biosafety designation requiring full-pressure-suit protection — requires recombinant expression systems that produce non-infectious antigen fragments rather than live virus components. The C1 platform's ability to express complex viral antigens in the quantities and quality needed for vaccine development research represents an important capability demonstration that extends the platform's global health application beyond conventional monoclonal antibody manufacturing into the more specialised domain of vaccine development for dangerous pathogens.
The Scripps Research Institute is among the world's leading biomedical research organisations in structural biology and viral antigen characterisation — its evaluation of Dyadic's C1-produced Bundibugyo antigens will constitute a technically rigorous quality assessment. If Scripps validates the antigen quality, structural integrity, and immunogenicity of the C1-produced product, that validation carries substantial scientific credibility that Dyadic can leverage in subsequent partnerships with government agencies and vaccine developers.
Building Toward Non-Dilutive Government Funding
The combination of the Gates Foundation grant and the Scripps Ebola antigen collaboration positions Dyadic International for a broader ecosystem of non-dilutive funding from government health agencies — specifically BARDA (Biomedical Advanced Research and Development Authority), NIH, USAID, and international equivalents — that fund the development of biological medical countermeasures for global health threats including Ebola and other emerging infectious diseases.
Government medical countermeasure contracts provide multi-year, non-dilutive revenue streams that are decoupled from the equity capital market cycles that typically constrain small-cap biotech companies' ability to fund R&D programmes through normal commercial timelines. For Dyadic, establishing the C1 platform's credibility in the Ebola antigen domain through the Scripps collaboration — while simultaneously building Gates Foundation credibility in the monoclonal antibody domain — creates a dual-channel institutional validation narrative that strengthens the case for BARDA and NIH contract awards.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial or investment advice. Readers should conduct their own due diligence before making investment decisions.






Please wait processing your request...